Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter W M Johnson

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2016
Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?Peter W M Johnson
Blood|June 23, 2022
Smart salvage treatment for Hodgkin lymphomaPeter W M Johnson
Hematology. American Society of Hematology. Education Program|December 10, 2013
Management of early-stage Hodgkin lymphoma: is there still a role for radiation?Peter W M Johnson
Hematological Oncology|June 9, 2023
Are we reaching the maximum cure rate for Hodgkin lymphoma?Peter W M Johnson
Hematological Oncology|June 11, 2015
IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate typesPeter W M Johnson
Current Oncology Reports|May 3, 2021
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted DrugsJemma Longley, Peter W M Johnson
BMJ (Clinical Research Ed.)|August 17, 2002
Bone marrow transplantsPeter W M Johnson, Kim Orchard
Hematological Oncology|June 13, 2019
Options for first line therapy of Hodgkin lymphomaJemma Longley, Peter W M Johnson
British Journal of Haematology|November 9, 2018
Current treatment paradigms for advanced stage Hodgkin lymphomaJemma Longley, Peter W M Johnson
Hematological Oncology|June 9, 2021
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cureJemma Longley, Peter W M Johnson
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Hematology. American Society of Hematology. Education Program|December 4, 2016
Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?Peter W M Johnson
Blood|June 23, 2022
Smart salvage treatment for Hodgkin lymphomaPeter W M Johnson
Hematology. American Society of Hematology. Education Program|December 10, 2013
Management of early-stage Hodgkin lymphoma: is there still a role for radiation?Peter W M Johnson
Hematological Oncology|June 9, 2023
Are we reaching the maximum cure rate for Hodgkin lymphoma?Peter W M Johnson
Hematological Oncology|June 11, 2015
IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate typesPeter W M Johnson
Current Oncology Reports|May 3, 2021
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted DrugsJemma Longley, Peter W M Johnson
BMJ (Clinical Research Ed.)|August 17, 2002
Bone marrow transplantsPeter W M Johnson, Kim Orchard
Hematological Oncology|June 13, 2019
Options for first line therapy of Hodgkin lymphomaJemma Longley, Peter W M Johnson
British Journal of Haematology|November 9, 2018
Current treatment paradigms for advanced stage Hodgkin lymphomaJemma Longley, Peter W M Johnson
Hematological Oncology|June 9, 2021
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cureJemma Longley, Peter W M Johnson
Pageof 11